The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 12, Pages 1677-1684
Publisher
Informa Healthcare
Online
2011-10-29
DOI
10.1517/13543784.2011.631523
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
- (2017) M. Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation
- (2011) John C. Araujo et al. CANCER BIOLOGY & THERAPY
- Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells
- (2011) A. R. Jensen et al. CLINICAL CANCER RESEARCH
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- HGF-independent potentiation of EGFR action by c-Met
- (2011) A M Dulak et al. ONCOGENE
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- Efficacy of c-Met inhibitor for advanced prostate cancer
- (2010) William H Tu et al. BMC CANCER
- miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo
- (2010) Gui Hu et al. CANCER BIOLOGY & THERAPY
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer
- (2010) B. Sen et al. CLINICAL CANCER RESEARCH
- Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met
- (2010) Cai INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Stromal Hyaluronan Interaction with Epithelial CD44 Variants Promotes Prostate Cancer Invasiveness by Augmenting Expression and Function of Hepatocyte Growth Factor and Androgen Receptor
- (2010) Shibnath Ghatak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
- (2010) Y. Dai et al. MOLECULAR CANCER THERAPEUTICS
- Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
- (2010) T. L. Burgess et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells
- (2010) L Xu et al. ONCOGENE
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer
- (2009) A. L. Russo et al. CLINICAL CANCER RESEARCH
- MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells
- (2009) Alessandro Salvi et al. FEBS Journal
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
- (2008) Na Li et al. CANCER LETTERS
- MicroRNAs Impair MET-Mediated Invasive Growth
- (2008) C. Migliore et al. CANCER RESEARCH
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer
- (2008) A. Gupta et al. CLINICAL CANCER RESEARCH
- Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer
- (2008) C. J. Logothetis et al. CLINICAL CANCER RESEARCH
- Targeting the c-MET signaling pathway for cancer therapy
- (2008) Xiangdong Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MicroRNAmiR-199a*Regulates theMETProto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2)
- (2008) Seonhoe Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer
- (2008) Kenji Yasuda et al. PROSTATE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now